IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEP 1 4 2006

In re Application of

Application No.: 10/696,011

Filing Date: October 29, 2003

Title: CRYSTALS OF INSULIN ANALOGS AND

PROCESSES FOR THEIR PREPARATION



Examiner:

Noakes, Suzanne M.

Art Unit:

1653

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

2006

Date of Denosit

Signature

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. §1.821(e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. §1.821(e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

Mark C. Nelligan, Reg. No.: 36,389 Attorney/Agent for Applicant

sanofi-aventis U.S. LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-2388
Telefax (908) 231-2626

Docket No. DEAV2002/0069US NP



PTO/SB/21 (09-04)

A3. 8

		11.5	Patent and			through 07/31/2006. OMB 0651-0031 J.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995	no person:	s are required to respond to a d	collection of in	formation	unless it	displays a valid OMB control number.
TRANSMITTAL FORM			10/696	10/696,011		
		Filing Date	Octobe	October 29, 2003		
		First Named Inventor	Harald	Harald BERCHTOLD et al.		
		Art Unit	1653			
(to be used for all correspondence after initial filing)		Examiner Name		NOAKES, Suzanne Marie		
Total Number of Pages in This Submission		Attorney Docket Number	DEAV2	DEAV2002/0069 US NP		
ENCLOSURES (Check all that apply)						
Fee Transmittal Form		•		Î	After A	Illowance Communication to TC
Fee Attached		Drawing(s) Licensing-related Papers				l Communication to Board eals and Interferences
					Appea	l Communication to TC
Amendment/Reply		Petition Petition to Convert to a		片	(Appea	l Notice, Brief, Reply Brief)
After Final	l L	Provisional Application			Proprie	etary Information
Affidavits/declaration(s)	🗀	Power of Attorney, Revocat Change of Correspondence	Address		Status	
Extension of Time Request	🔲 🤈	Terminal Disclaimer			Other below)	Enclosure(s) (please Identify
	F	Request for Refund				ard; Diskette of Sequence;
Express Abandonment Request		•				ment Re: Content of Paper
Information Disclosure Statement		CD, Number of CD(s)			Hamp	ant to 37C.F.R. 1.821(f); ston Research Protein
	L	Landscape Table on (CD		Crvsta	allization Formulas(1 page) +
Certified Copy of Priority Document(s)	Remar	rks				
Reply to Missing Parts/						
Incomplete Application Reply to Missing Parts						
under 37 CFR 1.52 or 1.53						
			•			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name AVENTIS PHARMAC	EUTICAL	LS INC.				
Signature All . C. Y	Tel	(,		·		
Printed name Mark C. Nelligan	/					
Date September 11, 2006			Reg. No.	36,38	39	
	-					
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is b sufficient postage as first class mail in an en	eing facsii velope add	mile transmitted to the USF dressed to: Commissioner	TO or depo for Patents,	sited with P.O. Box	the Un 1450, A	ited States Postal Service with Alexandria, VA 22313-1450 on
the date shown below: (USPTO FAX NO		Total No. of F)
Signature Server	_ h	Jalku				
Typed or printed name Generia Walke					Date	September 11, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.